Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8.6% | -44.6% | 30% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 48.3% | 48.9% | 71.3% | 60.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | $0 |
| % Margin | -23% | -17% | 32.8% | 15.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | $0 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -241.1% | -15.5% | 20% | 16.4% |
| EPS | -0 | -0 | 0 | 0 |
| % Growth | -1,618.3% | -140.9% | 57.7% | – |
| EPS Diluted | -0 | -0 | 0 | 0 |
| Weighted Avg Shares Out | 33 | 31 | 30 | 30 |
| Weighted Avg Shares Out Dil | 33 | 31 | 482 | 510 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -53.9% | -7.4% | 36.5% | 29.5% |